Advertisement
Screener

Grace Therapeutics, Inc. (GRCE) Weighted Average Remaining Contractual Life Of Outstanding Share Options

2.2 / 5 stars · 24/54 Roast Me

Grace Therapeutics, Inc. Weighted Average Remaining Contractual Life Of Outstanding Share Options

Grace Therapeutics, Inc. (GRCE) had Weighted Average Remaining Contractual Life Of Outstanding Share Options of 791.00% as of 2019-03-31, per its 20-F filed 2019-06-26.

Discontinued › Notes

ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions · last filed 2019-06-26

  • 2019-03-31: Weighted Average Remaining Contractual Life Of Outstanding Share Options 791.00%.
  • 2018-03-31: Weighted Average Remaining Contractual Life Of Outstanding Share Options 754.00%.
Period endWeighted Average Remaining Contractual Life Of Outstanding Share Options
2019-03-31791.00%
20-F · filed 2019-06-26
2018-03-31754.00%
20-F · filed 2018-06-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
PDS Biotechnology Corp (PDSB)United States$0.045B
SCYNEXIS INC (SCYX)United States$0.045B
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
VERU INC. (VERU)United States$0.043B-3.93
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Kairos Pharma, LTD. (KAPA)United States$0.041B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98